jimmy667 Thursday, 05/09/19 06:11:52 PM Re: DrHarleyboy post# 344 Post # of 393 Fairly decent guidance plus more in the pipeline and clinical readout before years end. Partnerships and collaborations in 5he works. $211 million in cash more that twice the after market Market Cap of the whole Company. Full year revenue for the current approved drug $10 million. That alone should justify the After Market MCap without the $211 mil cash. Add in the fact more trials underway for an already approved for one indication drug (easier path to approval) any plenty of cash and I can see Sell Side Wall street put a one year target of $400 mil MCap or $5.60 a share. Price targets are currently low $5 mid $8.80 high $14. Also there are 18 million shares short. When will they cover to take their profits and free up capital to move on to an over priced target? This After market was overdone. I bought in here. I am looking for a significant bounce as shorts buy to cover to take profits. This could be a great short term long trade and a fairly derisked intermediate trade going into the next round of clinical trial readouts. Certainly not selling into this over reaction. I feel this may have been priced in this week already and that tomorrow will be a relief rally and spark a short covering bounce as well. This stock is 56% owned by institutions they will not be flummoxed by this basically par earnings report. Sales are UP 38% from last quarter and acellerating and moving into international markets soon by partners. How many times have we seen After Market tanks turn into price rise the next day? 24.6% short or 18 million shares, wrap your mind around that.